← Leaderboards
Austin C Boese
Emory University
$151,841
Attributed
$151,841
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $59.6K · FY2020–22$100K$75K$50K$25K$0
'20
'21
'22
Funding mix
By agency
NIH$151,841 · 2
By mechanism
F99$94,288 · 1
F31$57,553 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Muxiang Zhou$8,074,026
- Sumin Kang$9,704,133
- Timothy L Lash$9,334,509
- Kevin C Ward$6,581,513
- Hyunsuk Shim$7,356,562
Others in their field
Other Emerging Leaders on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Jacob Ruff · Cornell University$22,500,000
- Elke Arenholz · Cornell University$14,750,000
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$14,335,772
- Amitinder Kaur · Tulane University Of Louisiana$12,771,713
Research focus
EnzymesExhibitsComplexDistantApoptoticAerobic GlycolysisAnoikisBioinformaticsCustomDisseminated Malignant NeoplasmBlood VesselsCancer CellCancer Cell LineBioenergeticsCancer PatientBiogenesisCancer TherapyCardiovascular SystemAntioxidantsCell DeathCellsCell SurvivalCessation Of LifeExperimental Study
Grant awards (4)
Metabolic reprogramming and tumor progression in LKB1 deficient NSCLC$46,752
F99 · FY2022 · CA · contact PI
Metabolic reprogramming and tumor progression in LKB1 deficient NSCLC$47,536
F99 · FY2021 · CA · contact PI
Role of SUCLA2 in anoikis resistance and tumor metastasis$12,033
F31 · FY2021 · CA · contact PI
Role of SUCLA2 in anoikis resistance and tumor metastasis$45,520
F31 · FY2020 · CA · contact PI